Clinical Researcher—August 2026 (Volume 40, Issue 4) PEER REVIEWED Inge Behroozfard Daraeikia, MPH; Kristi Prather, MPH; Elizabeth Bennett; Ashley Heath; Dr. Monica E. Lemmon, MD; Lindsey Spangler, JD; Dr. Geeta […]

Protocol amendments have evolved from an expected operational reality to a defining factor in clinical trial performance, cost, and site sustainability. Across sponsor, contract research organization, and site stakeholders, a consistent message is emerging: while amendments are often necessary, their frequency, timing, and execution are introducing significant downstream inefficiencies. The evidence is clear: protocol amendments are now a system-level challenge requiring coordinated, industry-wide solutions.

An electronic informed consent (eConsent) working group has developed a high-level framework for defining and measuring the impact of eConsent usage at clinical trial sites. This article outlines key success indicators, relevant metrics, and practical steps the industry can take to begin assessing the real-world impact of eConsent on site operations. As eConsent adoption matures, this high-level framework can evolve into a more complex key performance indicator infrastructure.